

Amendments to the Claims:

41.-48. (Canceled)

49. (Currently amended) A method of obtaining one or more human antibody molecules containing a binding site that binds human Fas, the method comprising

bringing into contact a population of human antibody molecules and a peptide of 10-20 amino acids in length which is a fragment of human Fas, ~~which said~~ fragment ~~comprises~~comprising an amino acid sequence selected from the group consisting of:

- (i) GQFCHKPCPPGERKARDCTV (SEQ ID NO. 1),
- (ii) QEGKEYTDKAHFSSKCRRCR (SEQ ID NO. 2),
- (iii) HFSSKCRRCRLCDEGHGLEV (SEQ ID NO. 3),
- (iv) EINCTRTQNTKCRCKPNFFC (SEQ ID NO. 4),
- (v) KCRCKPNFFCNSTVCEHCDP (SEQ ID NO. 5),
- (vi) WLCLLLLPIPLIVWVKRKEV (SEQ ID NO. 6),
- (vii) LIVWVKRKEVQKTCRKHRKE (SEQ ID NO. 7), and
- (viii) QKTCRKHRKE (SEQ ID NO. 9);

~~consists of an amino acid sequence selected from said group, or said fragment comprises~~comprising an immunogenic amino acid sequence which is found within an amino acid sequence selected from said group, ~~wherein the population of antibody molecules is obtained from a human prior to contact with a said peptide, and~~  
selecting one or more human antibody molecules able to bind said peptide.

2 50. (Currently amended) A method of according to claim 4640 wherein an antibody molecule directed to said peptide, or a mixture of antibody molecules directed to one or more said peptides, is obtained and is formulated into a composition comprising ~~at least one additional component a~~ pharmaceutically acceptable excipient, carrier, buffer or stabiliser.

51. (Cancelled)

52. (Cancelled)

3 53. (New) A method according to claim 49<sup>1</sup> further comprising providing host cells *in vitro* that produce the selected human antibody molecules able to bind said peptide.

4 54. (New) A method according to claim 53<sup>3</sup> wherein an antibody molecule directed to said peptide, or a mixture of antibody molecules directed at least one of said peptides, is obtained and is formulated into a composition comprising a pharmaceutically acceptable excipient, carrier, buffer or stabiliser.

C